Retevmo Adjuvant Therapy Improves Event-Free Survival in RET+ NSCLC
Retevmo adjuvant therapy has demonstrated a substantial event-free survival benefit in early-stage RET fusion-positive non-small cell lung cancer (NSCLC). Eli Lilly and Company announced positive topline results from the...

